Veru enters into clinical trial collaboration and supply agreement with eli lilly and company to evaluate enobosarm in combination with verzenio® in phase 3 enablar-2 trial

-- phase 3 enablar-2 clinical trial for 2 nd  line treatment of ar+er+her2- metastatic breast cancer expected to commence during first quarter of 2022 -- miami, feb. 01, 2022 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with eli lilly and company. the objective of the collaboration is to evaluate the efficacy and safety of enobosarm, veru's oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor (ar), a tumor suppressor, in combination with lilly's verzenio® (abemaciclib), a cdk4/6 inhibitor, as a second line therapy in the treatment of ar+er+her2- metastatic breast cancer.
VERU Ratings Summary
VERU Quant Ranking